A rituximab biosimilar has been approved by the FDA.

Overall survival was the sole US primary end point of the phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab and was not met.

Docirbrutinib generated responses in patients with relapsed/refractory CLL/SLL, MCL, and other non-Hodgkin lymphomas.

Shorter treatments of venetoclax plus azacitidine did not meet similarity criteria for longer treatments in Beat acute myeloid leukemia.

The FDA has granted orphan drug designation to enzomenib for acute lymphoblastic leukemia.

FDA has granted RMAT and fast track designations to celma-cel as a frontline consolidation in large B-cell lymphoma.

The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.

The top 5 OncLive TV videos of the week cover insights in pancreatic cancer, non–small cell lung cancer, the cost and value of immunotherapy, and bladder cancer.